Scotia Capital’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14M Buy
381,226
+61,064
+19% +$2.89M 0.06% 174
2025
Q4
$16.3M Buy
320,162
+153,275
+92% +$7.84M 0.07% 158
2025
Q3
$9.26M Sell
166,887
-24,460
-13% -$1.43M 0.04% 211
2025
Q2
$13.2M Sell
191,347
-20,863
-10% -$1.42M 0.06% 165
2025
Q1
$14.7M Sell
212,210
-73,581
-26% -$6.08M 0.08% 143
2024
Q4
$24.6M Buy
285,791
+5,833
+2% +$631K 0.13% 97
2024
Q3
$33.3M Buy
279,958
+31,462
+13% +$4.2M 0.18% 83
2024
Q2
$35.5M Buy
248,496
+25,768
+12% +$3.41M 0.21% 72
2024
Q1
$28.6M Buy
222,728
+17,204
+8% +$2.05M 0.17% 87
2023
Q4
$21.3M Buy
205,524
+71,720
+54% +$7.09M 0.14% 101
2023
Q3
$12.2M Sell
133,804
-4,834
-3% -$426K 0.09% 139
2023
Q2
$11.2M Sell
138,638
-216
-0.2% -$17.6K 0.08% 149
2023
Q1
$11M Sell
138,854
-20
-0% -$1.42K 0.08% 142
2022
Q4
$9.4M Sell
138,874
-4,476
-3% -$262K 0.07% 156
2022
Q3
$7.14M Sell
143,350
-710
-0.5% -$38K 0.06% 178
2022
Q2
$8.03M Sell
144,060
-9,942
-6% -$552K 0.06% 172
2022
Q1
$8.55M Sell
154,002
-8,496
-5% -$436K 0.05% 184
2021
Q4
$9.1M Buy
162,498
+778
+0.5% +$42.1K 0.06% 178
2021
Q3
$7.76M Buy
161,720
+7,984
+5% +$386K 0.06% 195
2021
Q2
$6.44M Buy
153,736
+12,538
+9% +$486K 0.05% 217
2021
Q1
$4.76M Sell
141,198
-1,308
-0.9% -$46.6K 0.04% 239
2020
Q4
$4.98M Sell
142,506
-3,194
-2% -$110K 0.05% 211
2020
Q3
$5.06M Sell
145,700
-498
-0.3% -$16.6K 0.05% 180
2020
Q2
$4.81M Sell
146,198
-3,944
-3% -$126K 0.07% 157
2020
Q1
$4.52M Buy
150,142
+1,810
+1% +$53.9K 0.06% 162
2019
Q4
$4.29M Sell
148,332
-2,954
-2% -$81.8K 0.05% 193
2019
Q3
$3.91M Sell
151,286
-7,938
-5% -$201K 0.05% 195
2019
Q2
$4.07M Sell
159,224
-36,804
-19% -$910K 0.05% 191
2019
Q1
$5.13M Sell
196,028
-65,814
-25% -$1.62M 0.07% 163
2018
Q4
$6.03M Sell
261,842
-58,198
-18% -$1.29M 0.09% 139
2018
Q3
$7.54M Sell
320,040
-35,656
-10% -$870K 0.1% 131
2018
Q2
$8.69M Sell
355,696
-1,286
-0.4% -$30.6K 0.12% 113
2018
Q1
$8.79M Sell
356,982
-7,168
-2% -$188K 0.12% 114
2017
Q4
$9.77M Sell
364,150
-17,980
-5% -$457K 0.13% 112
2017
Q3
$9.2M Buy
382,130
+48,370
+14% +$1.09M 0.13% 112
2017
Q2
$7.16M Buy
333,760
+14,000
+4% +$283K 0.12% 118
2017
Q1
$5.48M Buy
319,760
+15,044
+5% +$262K 0.09% 142
2016
Q4
$5.47M Sell
304,716
-55,398
-15% -$1M 0.09% 155
2016
Q3
$7.5M Buy
360,114
+67,472
+23% +$1.67M 0.14% 117
2016
Q2
$7.87M Buy
292,642
+13,892
+5% +$381K 0.16% 105
2016
Q1
$7.55M Buy
278,750
+93,322
+50% +$2.5M 0.17% 99
2015
Q4
$5M Hold
185,428
0.11% 150
2015
Q3
$5.03M Sell
185,428
-102,408
-36% -$2.9M 0.11% 142
2015
Q2
$7.85M Buy
287,836
+672
+0.2% +$18.9K 0.16% 113
2015
Q1
$7.67M Buy
287,164
+4,886
+2% +$113K 0.2% 87
2014
Q4
$5.97M Sell
282,278
-239,318
-46% -$5.35M 0.16% 94
2014
Q3
$12.4M Buy
521,596
+2,046
+0.4% +$47.1K 0.27% 67
2014
Q2
$12M Sell
519,550
-5,016
-1% -$111K 0.26% 67
2014
Q1
$12M Sell
524,566
-66,394
-11% -$1.41M 0.27% 63
2013
Q4
$10.9M Buy
590,960
+13,660
+2% +$238K 0.26% 65
2013
Q3
$9.77M Buy
577,300
+300,540
+109% +$5.05M 0.26% 63
2013
Q2
$4.29M Buy
+276,760
New +$4.61M 0.17% 93

Other funds holding NVO

Scotia Capital's NVO Position: Q1 2026 in Review

Scotia Capital increased its Novo Nordisk (NVO) stake by 19% in Q1 2026, buying an estimated $2.89M and bringing the position to 381,226 shares worth $14M. The position accounts for 0.06% of the portfolio, ranked #174.

Scotia Capital first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $35.5M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Scotia Capital held 381,226 shares of Novo Nordisk worth $14M as of Q1 2026.
  • Scotia Capital bought 61,064 Novo Nordisk shares in Q1 2026, an estimated $2.89M.
  • Novo Nordisk made up 0.06% of Scotia Capital's portfolio in Q1 2026, its #174 holding.
  • Scotia Capital first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Scotia Capital's Novo Nordisk position peaked at $35.5M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.